Digital asset treasury companies—DATs—are public equities whose main job is to accumulate crypto on the balance sheet. Strategy (formerly MicroStrategy) wrote the playbook. Raise capital, buy Bitcoin, and let the stock become a leveraged wrapper around the coins. Hundreds of imitators followed, wrapping ETH, SOL, HYPE, and more. The pitch to shareholders is simple: you get crypto exposure through a brokerage account, plus a corporate machine that can issue stock when the market is generous and buy more tokens when it is not.

The number that matters is mNAV: market cap divided by the net value of the crypto (and cash, minus debt and other claims). Above 1.0x, the stock trades at a premium to the pile. Below 1.0x, you are buying the coins cheaper than you could on an exchange—plus whatever operating story, staking yield, or capital-markets optionality the company still has.

That multiple is not a constant. It is a cycle.

In a roaring bull market, DATs often trade at a substantial premium of 2x to 3x. Investors pay extra for the “Saylor effect”: the ability to issue equity above NAV and recycle the proceeds into more coins, growing tokens per share. That flywheel is why some treasury stocks have, at times, crushed the underlying asset.

In a bear market the flywheel runs in reverse. Token prices fall. Equity risk premia blow out. Dilution fears and preferred-stock or debt obligations (where they exist) scare buyers away. Many DATs slump to 0.6x–0.9x mNAV—or worse. The same structure that amplified gains on the way up now prices in distress.

That is the setup. Near a cycle low, a discounted DAT is not just “cheap Bitcoin” or “cheap Solana.” It is a call option on two things happening at once: the asset recovering, and the wrapper re-rating from discount back toward parity or premium. If both occur, the stock can outpace the coin. If only the coin recovers and the multiple stays compressed, you still own the tokens at a discount—unless leverage, dilution, or a forced sale intervenes.

None of this is guaranteed. Spot ETFs already give clean, unlevered exposure. DATs add equity risk, issuance risk, and management risk. The opportunity is specifically the mean-reversion of mNAV layered on top of a crypto recovery.

Figures below are approximate as of late August 2026 and move daily with token prices, share counts, and preferred/debt adjustments. Always check a live tracker (Blockworks, DefiLlama, company 8-Ks) before acting.

Strategy (MSTR) — Bitcoin. This is the original DAT and still the largest: on the order of 840,000 BTC. Late-August trackers put outstanding equity mNAV around 0.80×—you pay roughly 80 cents for a dollar of Bitcoin on the common. That is the cleanest large-cap version of the article’s setup. The catch is capital structure. Strategy funds the stack with convertibles and preferreds (STRC and related), so enterprise mNAV (market cap + debt + preferred − cash) often sits much closer to 1.0×. Buying MSTR at an equity discount is leveraged BTC plus a claim that sits behind those senior instruments. If Bitcoin turns and the equity multiple only mean-reverts toward parity, MSTR can still beat spot; if preferreds and debt stay expensive to service in a long grind, the common stays the residual.

Metaplanet (MTPLF / 3350.T) — Bitcoin. Japan’s Strategy clone holds about 43,000 BTC, third among public companies. Basic/outstanding mNAV has recently printed in a wide band: ~0.66–0.68× on some U.S. scoreboards and closer to ~1.08× on diluted or different NAV methods. Treat it as “around or below NAV,” not a fire-sale 0.6× until you pick a definition. Average cost is well above current BTC, and the firm has used yen equity, rights, preferreds, and a BTC-backed credit line to keep buying. The cycle thesis is the same as MSTR’s, with extra Japan-market and FX noise: a re-rating of the wrapper plus a BTC bounce is how MTPLF outruns holding the coins in a yen or dollar account.

SharpLink (SBET) — Ethereum. Consensys-backed SharpLink is the No. 2 public ETH treasury after BMNR, with roughly 870,000–890,000 ETH (native plus liquid-staking equivalents) and nearly all of it staked. Recent trackers put outstanding mNAV around 0.82×–0.85×—about a 15–18% discount to the ETH pile. Cost basis is well above spot, so the stock still embeds a large unrealized loss on the coins, but the wrapper itself is cheap: you are paying less than a dollar for a dollar of ETH-plus-cash, with staking rewards accruing to shareholders. If ETH turns and the multiple only returns to 1.0×, SBET can outrun spot ether. Fully diluted mNAV will look less cheap if warrants from the June 2026 raise are counted.

Forward Industries (FWDI) — Solana. This is the clearest “discount to NAV” name of the four. FWDI holds roughly 7.5–7.8 million SOL (plus staking rewards), the largest public SOL treasury. Outstanding mNAV has recently printed around 0.67x, with fully diluted mNAV closer to 0.89x after warrants and options. Company materials around June 30 showed fully diluted mNAV near 0.91x at then-prevailing prices. Management has said it will issue stock above 1.0x and repurchase below—exactly the cycle-aware playbook. High cost basis from the initial 2025 buy (well above current SOL) is the scar. The opportunity is that you are still paying well under a dollar for a dollar of SOL-plus-cash, with tokens-per-share still growing.

DeFi Development Corp. (DFDV) — Solana. DFDV is the second-largest public SOL treasury after FWDI, holding about 2.3 million SOL and equivalents, with validator/staking yield on top of the stack. The Block recently showed mNAV near 0.58×; DefiLlama’s realized figure is about 0.66×. Either way it is a deep discount—deeper than FWDI on a basic multiple. Average purchase price is still far above current SOL, and convertibles/ELOC issuance make fully converted mNAV the number that matters. Management’s own KPI is SOL per share (SPS), not just pile size. For the article’s cycle thesis, DFDV is the high-beta SOL wrapper: a re-rating from ~0.6× toward parity plus a SOL bounce is how the equity can beat holding the token.

There are quite a few smaller cryptocurrency digital asset companies that investors can consider. They will have varying levels of risk, which helps to explain the deep discounts to NAV in some instances. But the graphic below is a good starting point for risk-tolerant investors looking for leveraged returns from the next cryptocurrency bull cycle.

Suppose a DAT trades at 0.70x mNAV and the token doubles. If the multiple only returns to 1.0x, the stock more than doubles. If risk appetite returns and the multiple goes to 1.3x—the kind of premium DATs enjoyed in the last up-cycle—the equity can do 2.5x–3x while the coin does 2x. That is the leveraged-gains argument in one paragraph.

The reverse is just as real. Token flat, multiple stays at 0.70x: you underperform a spot ETF and eat corporate overhead. Token down another 40%, mNAV compresses further, and the company issues stock into weakness: you get diluted into a hole. Preferred dividends or convertibles (more an MSTR/ASST) can force hard choices if the discount persists.

The thesis only works if two conditions hold. First, you are not catching a falling knife in a company that must sell coins to stay alive. Look at cash vs. obligations, and whether buybacks happen when mNAV is below 1. Second, the next bull market has to re-rate wrappers, not just tokens. Spot ETFs have already stolen the “I just want Bitcoin in my IRA” bid. DATs now have to justify a premium with tokens-per-share growth, staking income, or a narrative the market still pays for.

DATs are not magic. They are listed holding companies with a reflexive multiple. The historic pattern is that the multiple is mean-reverting: punished in bears, rewarded in bulls. Buying when that multiple is depressed—and when the underlying market looks washed out—is how the structure can outrun simply holding the coins. Position size accordingly. These are high-beta equities, not ETFs.

If you’d like to see our highest-conviction crypto, technology, and commodity ideas, you can upgrade to our premium membership.

Cheers,

 Jason Hamlin, Founder, Nicoya Research